Ovarian cancer: Is dose intensity dead?

Journal of Clinical Oncology

Volumn 25, Issue 27, 2007, Pages 4157-4158

  Ozols, Robert F ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; GEMCITABINE; MELPHALAN; MITOXANTRONE; PACLITAXEL;

AREA UNDER THE CURVE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; EDITORIAL; FOLLOW UP; HUMAN; INTENSIVE CARE; MULTIPLE CYCLE TREATMENT; OVARIECTOMY; OVARY CANCER; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SUPPORT GROUP; TREATMENT OUTCOME; DRUG ADMINISTRATION; FEMALE; MORTALITY; NOTE; OVARY TUMOR; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; REMISSION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 34948858445     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.1723     Document Type: Editorial

References (17)

1. Levin L, Hryniuk WM: Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5:756-767, 1987
2. Möbus V, Wandt H, Frickhofen N, et al: High-dose sequential chemotherapy with peripheral blood steam cell support compared with standard dose chemotherapy for first line treatment of advanced ovarian cancer: Results of a phase III Intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol 25:4187-493, 2007
3. Thigpen JT: Dose-intensity in ovarian carcinoma: Hold, enough? J Clin Oncol 15:1291-1293, 1997
4. McGuire WP, Hoskins WJ, Brady MF, et al: Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 13:1589-1599, 1995
5. Curé H, Battista C, Guastalla JP, et al: Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC study. J Clin Oncol 22:450s, 2004 (abstr 5006)
6. Stiff PJ, Bayer R, Kerger C, et al: High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: A multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 15:1309-1317, 1997
7. Stiff PJ, Veum-Stone J, Lazarus HM, et al: High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: An autologous blood and marrow transplant registry report. Ann Intern Med 133:504-514, 2000
8. Ledermann JA, Herd R, Maraninchi D, et al: High-dose chemotherapy for ovarian carcinoma: Long-term results from the solid tumor registry of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 12:693-699, 2001
9. Aghajanian C, Fennelly D, Shapiro F, et al: Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-oell support as primary treatment for patients with advanced ovarian cancer. J Clin Oncol 16:1852-1860, 1998
10. Schilder RJ, Brady MF, Spriggs D, et al: Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 88:3-8, 2003
11. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200, 2003
12. Jodrell DI, Egorin MJ, Canetta RM, et al: Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520-528, 1992
13. Bookman MA, McGuire WP, Kilpatrick D, et al: Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group. J Clin Oncol 14:1895-1902, 1996
14. Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43, 2006
15. Ozols RF, Bookman MA, Young RC: Intraperitoneal cisplatin therapy in ovarian cancer: Comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol 103:1-6, 2006
16. Gore M, du Bois A, Vergote I: Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol 24:4528-4530, 2006
17. Bookman MA for the Gynecologic Cancer InterGroup (GCIG) through the Gynecologic Oncology Group (GOG): GOGO 182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-liposomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. J Clin Oncol 24:456s, 2006 (suppl; abstr 5002)